Wei-Wu He Buys 1,871,605 Shares of CASI Pharmaceuticals Inc (CASI) Stock

CASI Pharmaceuticals Inc (NASDAQ:CASI) Director Wei-Wu He purchased 1,871,605 shares of the firm’s stock in a transaction on Monday, October 3rd. The shares were purchased at an average price of $1.19 per share, for a total transaction of $2,227,209.95. Following the completion of the purchase, the director now directly owns 24,698 shares of the company’s stock, valued at $29,390.62. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

CASI Pharmaceuticals Inc (NASDAQ:CASI) opened at 1.22 on Friday. The firm’s market capitalization is $60.34 million. CASI Pharmaceuticals Inc has a 1-year low of $0.58 and a 1-year high of $1.82. The firm’s 50-day moving average price is $1.12 and its 200-day moving average price is $1.18.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its quarterly earnings data on Monday, August 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.04. On average, equities research analysts predict that CASI Pharmaceuticals Inc will post ($0.28) EPS for the current fiscal year.

Separately, Maxim Group initiated coverage on CASI Pharmaceuticals in a research note on Wednesday, September 21st. They set a “buy” rating and a $4.00 price target on the stock.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

5 Day Chart for NASDAQ:CASI

Receive News & Ratings for CASI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.